Advertisement

Archives of Pharmacal Research

, Volume 38, Issue 5, pp 893–903 | Cite as

Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin

  • Wonhwa Lee
  • Sae-Kwang Ku
  • Jong-Sup BaeEmail author
Research Article

Abstract

Baicalin is a flavonoid compound purified from the medicinal plant Scutellaria baicalensis Georgi and has been reported to possess anti-inflammatory and anti-viral activities. However, antiplatelet, anticoagulant, and profibrinolytic properties of baicalin have not been studied. In this study, the anticoagulant and antiplatelet activities of baicalin were measured by monitoring activated partial thromboplastin-time (aPTT), prothrombin time (PT), the activities of cell-based thrombin and activated factor X (FXa), platelet aggregation and thrombus formation. The effects of baicalin on the expressions of plasminogen activator inhibitor type 1 (PAI-1) and tissue-type plasminogen activator (t-PA) were also tested in tumor necrosis factor-α (TNF-α) activated human umbilical vein endothelial cells (HUVECs). Our data showed that baicalin inhibited thrombin-catalyzed fibrin polymerization and platelet functions, prolonged aPTT and PT significantly and inhibited the activities and production of thrombin and FXa. Baicalin also prolonged in vivo bleeding time and inhibited TNF-α induced PAI-1 production. Furthermore, PAI-1/t-PA ratio was significantly decreased by baicalin. Collectively, these results indicate that baicalin possesses antithrombotic activities and suggest that the current study could provide bases for the development of new anticoagulant agents.

Keywords

Baicalin Fibrinolysis Anticoagulant Platelet 

Notes

Acknowledgments

This study was supported by the National Research Foundation of Korea (NRF) funded by the Korea government [MSIP] (Grant no. 2013-067053).

Conflict of interest

The authors have no conflict of interest to declare.

References

  1. Berk, B.C., J.I. Abe, W. Min, J. Surapisitchat, and C. Yan. 2001. Endothelial atheroprotective and anti-inflammatory mechanisms. Annals of the New York Academy of Sciences 947, 93–109. discussion 109–11.Google Scholar
  2. Boullin, D.J., A.R. Green, and K.S. Price. 1972. The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1. Journal of Physiology 221: 415–426.CrossRefPubMedCentralPubMedGoogle Scholar
  3. Chen, Y.C., S.C. Shen, L.G. Chen, T.J. Lee, and L.L. Yang. 2001. Wogonin, baicalin, and baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide. Biochemical Pharmacology 61: 1417–1427.CrossRefPubMedGoogle Scholar
  4. Chiu, J.H., I.S. Lay, M.Y. Su, H.L. Chiu, A.C. Chiu, W.Y. Lui, and C.W. Wu. 2002. Tumor necrosis factor-producing activity of wogonin in RAW 264.7 murine macrophage cell line. Planta Medica 68: 1036–1039.CrossRefPubMedGoogle Scholar
  5. Dahlback, B. 2000. Blood coagulation. Lancet 355: 1627–1632.CrossRefPubMedGoogle Scholar
  6. Davie, E.W. 1995. Biochemical and molecular aspects of the coagulation cascade. Thrombosis and Haemostasis 74: 1–6.PubMedGoogle Scholar
  7. Davie, E.W., K. Fujikawa, and W. Kisiel. 1991. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30: 10363–10370.CrossRefPubMedGoogle Scholar
  8. Day, S.M., J.L. Reeve, D.D. Myers, and W.P. Fay. 2004. Murine thrombosis models. Thrombosis and Haemostasis 92: 486–494.PubMedGoogle Scholar
  9. Dejana, E., A. Callioni, A. Quintana, and G. De Gaetano. 1979. Bleeding time in laboratory animals. II—A comparison of different assay conditions in rats. Thrombosis Research 15: 191–197.CrossRefPubMedGoogle Scholar
  10. Despotis, G.J., G. Gravlee, K. Filos, and J. Levy. 1999. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 91: 1122–1151.CrossRefPubMedGoogle Scholar
  11. Esmon, C.T. 2005. The interactions between inflammation and coagulation. British Journal of Haematology 131: 417–430.CrossRefPubMedGoogle Scholar
  12. Esmon, C.T., K. Fukudome, T. Mather, W. Bode, L.M. Regan, D.J. Stearns-Kurosawa, and S. Kurosawa. 1999. Inflammation, sepsis, and coagulation. Haematologica 84: 254–259.PubMedGoogle Scholar
  13. Fareed, J., I. Thethi, and D. Hoppensteadt. 2012. Old versus new oral anticoagulants: focus on pharmacology. Annual Review of Pharmacology and Toxicology 52: 79–99.CrossRefPubMedGoogle Scholar
  14. Fares, A. 2013. Winter cardiovascular diseases phenomenon. N Am J Med Sci 5: 266–279.CrossRefPubMedCentralPubMedGoogle Scholar
  15. Fischer, K.G. 2007. Essentials of anticoagulation in hemodialysis. Hemodial Int 11: 178–189.CrossRefPubMedGoogle Scholar
  16. Ghosh, S., M. Ezban, E. Persson, U. Pendurthi, U. Hedner, and L.V. Rao. 2007. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. Journal of Thrombosis and Haemostasis 5: 336–346.CrossRefPubMedGoogle Scholar
  17. Goto, S., N. Tamura, and H. Ishida. 2004. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. Journal of the American College of Cardiology 44: 316–323.CrossRefPubMedGoogle Scholar
  18. Hamaguchi, E., T. Takamura, A. Shimizu, and Y. Nagai. 2003. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. Journal of Pharmacology and Experimental Therapeutics 307: 987–994.CrossRefPubMedGoogle Scholar
  19. Harbrecht, U. 2011. Old and new anticoagulants. Hamostaseologie 31: 21–27.CrossRefPubMedGoogle Scholar
  20. Hirano, T., S. Higa, J. Arimitsu, T. Naka, A. Ogata, Y. Shima, M. Fujimoto, T. Yamadori, T. Ohkawara, Y. Kuwabara, M. Kawai, H. Matsuda, M. Yoshikawa, N. Maezaki, T. Tanaka, and I. Kawase. 2006. Luteolin, a flavonoid, inhibits AP-1 activation by basophils. Biochem Biophys Res Commun 340: 1–7.CrossRefPubMedGoogle Scholar
  21. Izuhara, Y., S. Takahashi, M. Nangaku, S. Takizawa, H. Ishida, K. Kurokawa, C. Van Ypersele De Strihou, N. Hirayama, and T. Miyata. 2008. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arteriosclerosis, Thrombosis, and Vascular Biology 28, 672–677.Google Scholar
  22. Jauch, E.C., J.L. Saver, H.P. Adams Jr, A. Bruno, J.J. Connors, B.M. Demaerschalk, P. Khatri, P.W. Mcmullan Jr, A.I. Qureshi, K. Rosenfield, P.A. Scott, D.R. Summers, D.Z. Wang, M. Wintermark, and H. Yonas. 2013. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44: 870–947.CrossRefPubMedGoogle Scholar
  23. Kaiser, L., and H.V. Sparks Jr. 1987. Endothelial cells. Not just a cellophane wrapper. Archives of Internal Medicine 147: 569–573.CrossRefPubMedGoogle Scholar
  24. Kim, D.C., S.K. Ku, and J.S. Bae. 2012a. Anticoagulant activities of curcumin and its derivative. BMB Rep 45: 221–226.CrossRefPubMedGoogle Scholar
  25. Kim, D.S., E.J. Son, M. Kim, Y.M. Heo, J.B. Nam, J.Y. Ro, and S.S. Woo. 2010. Antiallergic herbal composition from Scutellaria baicalensis and Phyllostachys edulis. Planta Medica 76: 678–682.CrossRefPubMedGoogle Scholar
  26. Kim, S.Y., S. Kim, J.M. Kim, E.H. Jho, S. Park, D. Oh, and H.S. Yun-Choi. 2011. PKC inhibitors RO 31-8220 and Go 6983 enhance epinephrine-induced platelet aggregation in catecholamine hypo-responsive platelets by enhancing Akt phosphorylation. BMB Rep 44: 140–145.CrossRefPubMedGoogle Scholar
  27. Kim, T.H., S.K. Ku, and J.S. Bae. 2012b. Antithrombotic and profibrinolytic activities of eckol and dieckol. Journal of Cellular Biochemistry 113: 2877–2883.CrossRefPubMedGoogle Scholar
  28. Ku, S.K., I.C. Lee, and JS. Bae. 2013. Antithrombotic activities of oroxylin A in vitro and in vivo. Archives of Pharmacal Research 33(5):787–792.Google Scholar
  29. Kubo, M., H. Matsuda, M. Tanaka, Y. Kimura, H. Okuda, M. Higashino, T. Tani, K. Namba, and S. Arichi. 1984. Studies on Scutellariae radix. VII. Anti-arthritic and anti-inflammatory actions of methanolic extract and flavonoid components from Scutellariae radix. Chem Pharm Bull (Tokyo) 32: 2724–2729.CrossRefGoogle Scholar
  30. Lee, K.H. 2000. Research and future trends in the pharmaceutical development of medicinal herbs from Chinese medicine. Public Health Nutr 3: 515–522.CrossRefPubMedGoogle Scholar
  31. Lee, W., S.K. Ku, and J.S. Bae. 2013. Emodin-6-O-beta-D-glucoside down-regulates endothelial protein C receptor shedding. Arch Pharm Res 36: 1160–1165.CrossRefPubMedGoogle Scholar
  32. Lee, W., E.J. Yang, S.K. Ku, K.S. Song, and J.S. Bae. 2012. Anticoagulant activities of oleanolic acid via inhibition of tissue factor expressions. BMB Rep 45: 390–395.CrossRefPubMedGoogle Scholar
  33. Li, B.Q., T. Fu, W.H. Gong, N. Dunlop, H. Kung, Y. Yan, J. Kang, and J.M. Wang. 2000. The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines. Immunopharmacology 49: 295–306.CrossRefPubMedGoogle Scholar
  34. Li, Y., Z.J. Qian, B. Ryu, S.H. Lee, M.M. Kim, and S.K. Kim. 2009. Chemical components and its antioxidant properties in vitro: an edible marine brown alga. Ecklonia cava. Bioorg Med Chem 17: 1963–1973.CrossRefGoogle Scholar
  35. Liu, W., M. Kato, A.A. Akhand, A. Hayakawa, M. Takemura, S. Yoshida, H. Suzuki, and I. Nakashima. 1998. The herbal medicine sho-saiko-to inhibits the growth of malignant melanoma cells by upregulating Fas-mediated apoptosis and arresting cell cycle through downregulation of cyclin dependent kinases. International Journal of Oncology 12: 1321–1326.PubMedGoogle Scholar
  36. Lopez, S., F. Peiretti, B. Bonardo, I. Juhan-Vague, and G. Nalbone. 2000. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152: 359–366.CrossRefPubMedGoogle Scholar
  37. Mann, K.G., K. Brummel, and S. Butenas. 2003. What is all that thrombin for? Journal of Thrombosis and Haemostasis 1: 1504–1514.CrossRefPubMedGoogle Scholar
  38. Middleton Jr, E., and G. Drzewiecki. 1984. Flavonoid inhibition of human basophil histamine release stimulated by various agents. Biochemical Pharmacology 33: 3333–3338.CrossRefPubMedGoogle Scholar
  39. Monroe, D.M., M. Hoffman, and H.R. Roberts. 2002. Platelets and thrombin generation. Arteriosclerosis, Thrombosis, and Vascular Biology 22: 1381–1389.CrossRefPubMedGoogle Scholar
  40. Mukaida, N. 2000. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. International Journal of Hematology 72: 391–398.PubMedGoogle Scholar
  41. Nowak, P., H.M. Zbikowska, M. Ponczek, J. Kolodziejczyk, and B. Wachowicz. 2007. Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: functional consequences. Thrombosis Research 121: 163–174.CrossRefPubMedGoogle Scholar
  42. Philip-Joet, F., M.C. Alessi, C. Philip-Joet, M. Aillaud, J.R. Barriere, A. Arnaud, and I. Juhan-Vague. 1995. Fibrinolytic and inflammatory processes in pleural effusions. European Respiratory Journal 8: 1352–1356.CrossRefPubMedGoogle Scholar
  43. Popa, C., M.G. Netea, P.L. Van Riel, J.W. Van Der Meer, and A.F. Stalenhoef. 2007. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. Journal of Lipid Research 48: 751–762.CrossRefPubMedGoogle Scholar
  44. Quinn, C., J. Hill, and H. Hassouna. 2000. A guide for diagnosis of patients with arterial and venous thrombosis. Clin Lab Sci 13: 229–238.PubMedGoogle Scholar
  45. Rao, L.V., S.I. Rapaport, and M. Lorenzi. 1988. Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 71: 791–796.PubMedGoogle Scholar
  46. Ross, R. 1999. Atherosclerosis–an inflammatory disease. New England Journal of Medicine 340: 115–126.CrossRefPubMedGoogle Scholar
  47. Sachs, U.J., and B. Nieswandt. 2007. In vivo thrombus formation in murine models. Circulation Research 100: 979–991.CrossRefPubMedGoogle Scholar
  48. Schleef, R.R., M.P. Bevilacqua, M. Sawdey, M.A. Gimbrone Jr, and D.J. Loskutoff. 1988. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. Journal of Biological Chemistry 263: 5797–5803.PubMedGoogle Scholar
  49. Schouten, M., W.J. Wiersinga, M. Levi, and T. Van Der Poll. 2008. Inflammation, endothelium, and coagulation in sepsis. Journal of Leukocyte Biology 83: 536–545.CrossRefPubMedGoogle Scholar
  50. Sugo, T., C. Nakamikawa, S. Tanabe, and M. Matsuda. 1995. Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: its catalytic efficiency is similar to that of prothrombinase complex on platelets. Journal of Biochemistry 117: 244–250.CrossRefPubMedGoogle Scholar
  51. Sun, J., L. Li, J. Wu, B. Liu, W. Gong, Y. Lv, Q. Luo, X. Duan, and J. Dong. 2013. Effects of baicalin on airway remodeling in asthmatic mice. Planta Medica 79: 199–206.CrossRefPubMedGoogle Scholar
  52. Van Den Berg, E.A., E.D. Sprengers, M. Jaye, W. Burgess, T. Maciag, and V.W. Van Hinsbergh. 1988. Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells. Thrombosis and Haemostasis 60: 63–67.PubMedGoogle Scholar
  53. Van Hinsbergh, V.W., T. Kooistra, E.A. Van Den Berg, H.M. Princen, W. Fiers, and J.J. Emeis. 1988. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72: 1467–1473.PubMedGoogle Scholar
  54. Westrick, R.J., M.E. Winn, and D.T. Eitzman. 2007. Murine models of vascular thrombosis (Eitzman series). Arteriosclerosis, Thrombosis, and Vascular Biology 27: 2079–2093.CrossRefPubMedGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2014

Authors and Affiliations

  1. 1.College of Pharmacy, CMRI, Research Institute of Pharmaceutical SciencesKyungpook National UniversityDaeguRepublic of Korea
  2. 2.BK21 Plus KNU Biomedical Convergence Program, Department of Biochemistry and Cell Biology, School of MedicineKyungpook National UniversityDaeguRepublic of Korea
  3. 3.Department of Anatomy and Histology, College of Korean MedicineDaegu Haany UniversityGyeongsanRepublic of Korea

Personalised recommendations